Double trouble for tumours: Exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses

被引:26
作者
De Silva, Naomi [1 ,2 ]
Atkins, Harold [2 ]
Kirn, David H. [3 ]
Bell, John C. [1 ,2 ,3 ]
Breitbach, Caroline J. [3 ]
机构
[1] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8L1, Canada
[2] Ottawa Hosp, Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada
[3] Jennerex Inc, San Francisco, CA USA
关键词
HERPES-SIMPLEX-VIRUS; CELL-BASED DELIVERY; PROSTATE-CANCER; VIRAL ONCOLYSIS; IN-VIVO; THERAPY; ADENOVIRUS; EFFICACY; EXPRESSION; ANGIOGENESIS;
D O I
10.1016/j.cytogfr.2010.02.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Oncolytic viruses (OVs) are selected based on their ability to eliminate malignancies by direct infection and lysis of cancer cells. Originally, OVs were designed to target malignancies by taking advantage of the defects of cancer cells observed in vitro. Subsequent analysis of virus delivery and spread in vivo has demonstrated that the tumour microenvironment can impede the ability of OVs to effectively infect and spread. Despite this limitation, it is becoming increasingly evident that OVs are also able to take advantage of certain features of the tumour microenvironment. Currently, a growing body of the literature is delineating the complex interaction between OVs and the tumour microenvironment that results in an additional therapeutic activity; these viruses are able to target malignancies by rapidly altering the tumour microenvironment into a milieu that potentiates anticancer activity. Herein, we discuss strategies that capitalize on the multifaceted relationship between OVs and host-tumour interactions that enhance the toxicity of OVs to the tumour microenvironment. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:135 / 141
页数:7
相关论文
共 62 条
[1]
Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide [J].
Aghi, Manish ;
Rabkin, Samuel D. ;
Martuza, Robert L. .
CANCER RESEARCH, 2007, 67 (02) :440-444
[2]
Blood clearance rates of adenovirus type 5 in mice [J].
Alemany, R ;
Suzuki, K ;
Curiel, DT .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :2605-2609
[3]
ALTOMONTE J, 2008, CANC GENE THER OCT
[4]
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo [J].
Altomonte, Jennifer ;
Wu, Lan ;
Chen, Li ;
Meseck, Marcia ;
Ebert, Oliver ;
Garcia-Sastre, Adolfo ;
Fallon, John ;
Woo, Savio L. C. .
MOLECULAR THERAPY, 2008, 16 (01) :146-153
[5]
HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer [J].
Benencia, F ;
Courrèges, MC ;
Conejo-García, JR ;
Mohamed-Hadley, A ;
Zhang, L ;
Buckanovich, RJ ;
Carroll, R ;
Fraser, N ;
Coukos, G .
MOLECULAR THERAPY, 2005, 12 (05) :789-802
[6]
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow [J].
Breitbach, Caroline J. ;
Paterson, Jennifer M. ;
Lemay, Chantal G. ;
Falls, Theresa J. ;
McGuire, Allison ;
Parato, Kelley A. ;
Stojdl, David F. ;
Daneshmand, Manijeh ;
Speth, Kelly ;
Kirn, David ;
McCart, J. Andrea ;
Atkins, Harold ;
Bell, John C. .
MOLECULAR THERAPY, 2007, 15 (09) :1686-1693
[7]
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide [J].
Currier, Mark A. ;
Gillespie, Rebecca A. ;
Sawtell, Nancy M. ;
Mahller, Yonatan Y. ;
Stroup, Greg ;
Collins, Margaret H. ;
Kambara, Hirokazu ;
Chiocca, E. Antonio ;
Cripe, Timothy P. .
MOLECULAR THERAPY, 2008, 16 (05) :879-885
[9]
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma [J].
Errington, F. ;
White, C. L. ;
Twigger, K. R. ;
Rose, A. ;
Scott, K. ;
Steele, L. ;
Ilett, L. J. ;
Prestwich, R. ;
Pandha, H. S. ;
Coffey, M. ;
Selby, P. ;
Vile, R. ;
Harrington, K. J. ;
Melcher, A. A. .
GENE THERAPY, 2008, 15 (18) :1257-1270
[10]
Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy [J].
Frentzen, Alexa ;
Yu, Yong A. ;
Chen, Nanhai ;
Zhang, Qian ;
Weibel, Stephanie ;
Raab, Viktoria ;
Szalay, Aladar A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (31) :12915-12920